Buscar
Eupraxia Pharmaceuticals Inc
EPRXAñadir a la lista de seguimiento
6.400USD
-0.150-2.29%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
416.54MCap. mercado
PérdidaP/E TTM
Más Datos de Eupraxia Pharmaceuticals Inc Compañía
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Información de Eupraxia Pharmaceuticals Inc
Símbolo de cotizaciónEPRX
Nombre de la empresaEupraxia Pharmaceuticals Inc
Fecha de salida a bolsaMar 09, 2021
Director ejecutivoHelliwell (James A)
Número de empleados33
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 09
Dirección201-2067 Cadboro Bay Rd.
CiudadVICTORIA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV8R 5G4
Teléfono12505903968
Sitio Webhttps://eupraxiapharma.com/home/default.aspx
Símbolo de cotizaciónEPRX
Fecha de salida a bolsaMar 09, 2021
Director ejecutivoHelliwell (James A)
Ejecutivos de Eupraxia Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
18.86K
+13.07%
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.47%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
18.86K
+13.07%
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Eupraxia Pharmaceuticals Inc?
Los cinco principales accionistas de Eupraxia Pharmaceuticals Inc son: Dr. Michael Wilmink, M.D.
¿Cuántas instituciones poseen acciones de Eupraxia Pharmaceuticals Inc (EPRX)?
A fecha de 2026Q1, 56 instituciones poseen acciones de Eupraxia Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 19.60M, lo que representa el 32.43% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 818141.00.